Early commercial results reveal the gap between a pressing medical need and the manufacturing reliability and hospital adoption required to build a business.
An engineered blood vessel approved by the U.S. Food and Drug Administration in December 2024 generated about $0.9 million in sales during the first half of 2026, according to its maker, Humacyte. Meanwhile, more than 109,000 people in the United States were waiting for an organ in early 2026, according to federal data cited by Mayo Clinic. The contrast highlights a central challenge for the field: a documented medical need does not automatically translate into a market. Lab-grown tissue must first be made reliably and then adopted by hospitals, and early commercial results show that both steps take time.
A shortage that growth has not closed
The shortage persists even though the transplant system is expanding. U.S. surgeons performed 46,750 solid-organ transplants in 2024, up from 29,768 in 2013, according to the 2024 annual report from the Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network. Yet waiting lists have grown. The figures show that rising transplant volumes have not kept pace with demand.
What lab-grown means today
The term lab-grown covers products at very different stages. Humacyte’s vessel, Symvess, is made from human donor cells that are then removed, leaving a scaffold that a patient’s own tissue can populate. Its FDA-approved use is limited to treating extremity arterial injuries when the patient’s own vein is not a suitable option.
Vertex Pharmaceuticals’ zimislecel, a type 1 diabetes therapy derived from stem cells, is in pivotal testing. Whole organs grown in a laboratory are not yet an approved treatment option. The products nearest patients therefore address specific injuries and diseases, not organ failure broadly.
The first gate: making a living product
Cell-based products can be harder to manufacture consistently than chemical drugs. Their biological starting materials can vary, and differences in inputs or production conditions can affect one batch’s characteristics compared with another’s. Manufacturers must demonstrate that their production processes consistently deliver products that meet required quality standards. Changes in manufacturing scale or production sites can require additional evidence that the resulting product remains comparable to the one evaluated in clinical studies. A company can therefore hold strong clinical results and still lack a validated process capable of supplying a market.
Vertex’s experience illustrates how closely a timeline depends on manufacturing. In March 2025 the company expected to submit zimislecel to regulators in 2026. It later temporarily paused completion of dosing in its pivotal study while conducting an internal manufacturing analysis. In May 202, Vertex said the analysis was complete and dosing had resumed, with updated timelines due later this year. The company has not disclosed what the analysis found, hence the nature of the issue remains unclear. What is clear from its updates is that dosing could not proceed as planned until the manufacturing review was completed.
The second gate: getting hospitals to buy
Clearing production does not guarantee orders, as U.S. hospitals generally route new products through value analysis committees, which weigh clinical evidence and cost against existing alternatives. Some also require additional review or a trial before approving a purchase. A product with a narrow indication and a boxed warning for graft failure, as Symvess carries, must persuade clinicians and finance staff that its benefit over existing options justifies the change. Because each hospital or health system decides separately, adoption tends to proceed one institution at a time.
Humacyte’s commercial results illustrate the gap between approval and use. Committee approval allows a hospital to consider purchasing a product; it does not guarantee that clinicians will use it or that orders will follow. Humacyte reported 27 committee approvals by March 2026, alongside sales of $0.5 million in the first quarter and $0.4 million in the second. In 2025, it expensed overhead associated with production capacity it was not using.
The company said the number of hospitals that have ordered Symvess rose from 34 at the end of the second quarter to 49 by Spet. 30, 2026, attributing the increase to a commercial strategy introduced in the second quarter. That increase suggests broader hospital reach, although order counts alone do not show how frequently the product is being used or whether adoption will translate into sustained revenue growth.
What executives should weigh
For investors, partners and hospital buyers, these cases suggest better questions than the size of the shortage alone. Can the manufacturer demonstrate a validated, repeatable process? How many hospitals have both approved the product and how many have placed orders? Are clinicians using it regularly, and does that use support the economics of production and distribution?
Narrow first indications also mean early revenue is likely to come from specific clinical niches, where evidence and purchasing decisions are easier to establish, rather than from organ replacement. Two companies cannot show how the whole sector will perform, but they illustrate hurdles other entrants are likely to meet.
The organ shortage explains why companies pursue lab-grown tissue, but it does not determine when those products will sell. Need becomes demand only after a product can be manufactured consistently and then approved and used by the hospitals that buy it. The evidence so far, a vessel with limited sales and a cell therapy whose timeline slipped, suggests that these steps set the pace. Whole-organ replacement would have to pass through the same gates.
